On Jun. 16, 2020, the University of Oxford reported that overall dexamethasone reduced the 28-day mortality rate by 17% with a highly significant trend showing greatest benefit among those patients requiring ventilation. But it is important to recognise that no evidence of benefit for patients who did not require oxygen and study patients were not studied outside the hospital setting.

The RECOVERY trial was a large, randomised controlled trial of possible treatments for patients admitted to hospital with COVID-19. Over 11,500 patients were randomised to the following treatment arms, or no additional treatment.